{"id":439829,"date":"2021-02-19T08:03:24","date_gmt":"2021-02-19T13:03:24","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=439829"},"modified":"2021-02-19T08:03:24","modified_gmt":"2021-02-19T13:03:24","slug":"pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\/","title":{"rendered":"Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch<\/b><\/p>\n<p>HAYWARD, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nPulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation\u2122 (NPS\u2122) technology, today announced that the first CellFX<sup>\u00ae <\/sup>procedures in the European Union were successfully completed. The initial commercial use of the non-thermal, cellular-focused CellFX System to clear common benign lesions, now expands the Company\u2019s controlled launch program starting with the top aesthetic dermatologists and plastic surgeons across Europe. This strategic rollout in Europe will run in parallel with the Company\u2019s U.S. controlled launch aimed at building a strong foundation of clinical and commercial advocacy as the Company grows a promising global business.\n<\/p>\n<p id=\"news-body-cta\">This press release features multimedia. View the full release here: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20210219005136\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210219005136\/en\/<\/a><\/p>\n<div id=\"bwbodyimg\" style=\"width: 480px;float:left;padding-left:0px;padding-right:20px;padding-top:0px;padding-bottom:0px\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210219005136\/en\/860125\/4\/pulse.jpg\" alt=\"(Photo: Business Wire)\" \/><\/p>\n<p style=\"font-size:85%\">(Photo: Business Wire)<\/p>\n<\/div>\n<p>\nAs the first-of-its-kind multi-application platform powered by NPS technology delivering nano-second pulses of electrical energy to non-thermally clear cells while protecting adjacent non-cellular healthy tissue, the CellFX System ushers in a new chapter in dermatology procedures addressing everyday skin lesions.\n<\/p>\n<p>\n\u201cI am delighted to be the first aesthetic skin specialist to perform the CellFX procedure in Europe. We see a huge number of patients who are burdened by troublesome skin lesions, such as sebaceous hyperplasia, seborrheic keratoses, and non-genital warts, that can affect them at home, work and socially,\u201d said Dr. Afschin Fatemi, medical director of The S-thetic Group, a network of aesthetic clinics across Germany. \u201cWith its non-thermal, cellular mechanism, the CellFX System provides a new, consistent solution to remove a variety of bumps and growths on the face and body that have been historically difficult to treat. I am excited to offer this innovative procedure in our clinics and look forward to the enhanced results and improved patient satisfaction we can expect to achieve.\u201d\n<\/p>\n<p>\nThe prevalence of SH, SK and common, non-genital warts among patients visiting aesthetic dermatologists today is widespread. Based on a 2020 survey among aesthetic physicians from Germany, Spain and France, an average of 200 patients per month who visit aesthetic dermatology practices present with each lesion type (SH, SK, non-genital warts). Further, patients place greater value on a procedure to treat skin lesions over other popular aesthetic procedures they currently receive and are willing to pay cash to treat multiple lesions in a single visit.<sup>1<\/sup><\/p>\n<p>\n&#8220;We are at the inception of a distinctive new era as we embark on the commercial use of the CellFX System for specific lesion types throughout the European Union. In partnership with leading aesthetic skin specialists across Europe, our ambition is to create a blueprint of best practices that ensures success for the next wave of early adopters,\u201d said Ed Ebbers, Executive Vice President and General Manager, Dermatology, of Pulse Biosciences. \u201cWe are honored to work with Dr. Fatemi and we look forward to a promising future in the European market.\u201d\n<\/p>\n<p><b>About Pulse Biosciences\u00ae <\/b><\/p>\n<p>\nPulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The CellFX\u00ae System is the first commercial product to harness the distinctive advantages of the Company\u2019s proprietary Nano-Pulse Stimulation<sup>TM<\/sup> (NPS<sup>TM<\/sup>) technology, such as the ability to non-thermally clear cells while sparing non-cellular tissue, to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model. To learn more, please visit pulsebiosciences.com.\n<\/p>\n<p>\nTo stay informed about the CellFX System, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cellfx.com&amp;esheet=52381911&amp;newsitemid=20210219005136&amp;lan=en-US&amp;anchor=CellFX.com&amp;index=1&amp;md5=c881a4c06c06e8e9d758216d91476894\">CellFX.com<\/a> and sign up for updates.\n<\/p>\n<p>\nPulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and\/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nAll statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to Pulse Biosciences\u2019 expectations regarding regulatory clearance and the timing of FDA, Health Canada and other regulatory filings or approvals, and the ability of the Company to successfully complete a 510(k) submission for the CellFX System or for any specific indications, the ability of the Company to prepare and provide data to FDA, Canadian and other regulatory bodies, NPS technology including the effectiveness of such technology and the effectiveness of related clinical studies in predicting outcomes resulting from the use of NPS technology, the CellFX System including the benefits of the CellFX System and commercialization of the CellFX System, current and planned future clinical studies and the ability of the Company to execute such studies and results of any such studies, other matters related to its pipeline of product candidates, the Company\u2019s market opportunity and commercialization plans, including the timing and results of the controlled launch in Europe, the market for the treatment of certain lesions, the experience of using the CellFX System, future financial performance, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences\u2019 current expectations, estimates, and projections regarding Pulse Biosciences\u2019 business, operations and other similar or related factors. Words such as \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201canticipate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences\u2019 control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences\u2019 filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.\n<\/p>\n<p><sup>1<\/sup> 2020 Physician (n=46) and Patient (n=190) surveys conducted in the EU by third-party market research firm on behalf of Pulse Biosciences, Inc.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210219005136r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210219005136\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210219005136\/en\/<\/a><\/span><\/p>\n<p><b>Investors:<br \/>\n<\/b><br \/>Pulse Biosciences<br \/>\n<br \/>Sandra Gardiner, EVP and CFO<br \/>\n<br \/>510.241.1077<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:IR@pulsebiosciences.com\">IR@pulsebiosciences.com<br \/>\n<\/a><br \/>or<br \/>\n<br \/>Gilmartin Group<br \/>\n<br \/>Philip Trip Taylor<br \/>\n<br \/>415.937.5406<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:philip@gilmartinir.com\">philip@gilmartinir.com<\/a><\/p>\n<p><b>Media:<br \/>\n<\/b><br \/>Tosk Communications<br \/>\n<br \/>Nadine D. Tosk<br \/>\n<br \/>504.453.8344<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:nadinepr@gmail.com\">nadinepr@gmail.com<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"mailto:press@pulsebiosciences.com\">press@pulsebiosciences.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Europe United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Other Health Medical Devices<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Photo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210219005136\/en\/860125\/3\/pulse.jpg\" alt=\"Photo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\">(Photo: Business Wire)<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch HAYWARD, Calif.&#8211;(BUSINESS WIRE)&#8211; Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation\u2122 (NPS\u2122) technology, today announced that the first CellFX\u00ae procedures in the European Union were successfully completed. The initial commercial use of the non-thermal, cellular-focused CellFX System to clear common benign lesions, now expands the Company\u2019s controlled launch program starting with the top aesthetic dermatologists and plastic surgeons across Europe. This strategic rollout in Europe will run in parallel with the Company\u2019s U.S. controlled launch aimed at building a strong foundation of clinical and commercial advocacy as the Company grows a promising global business. This press release features multimedia. View &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-439829","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch HAYWARD, Calif.&#8211;(BUSINESS WIRE)&#8211; Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation\u2122 (NPS\u2122) technology, today announced that the first CellFX\u00ae procedures in the European Union were successfully completed. The initial commercial use of the non-thermal, cellular-focused CellFX System to clear common benign lesions, now expands the Company\u2019s controlled launch program starting with the top aesthetic dermatologists and plastic surgeons across Europe. This strategic rollout in Europe will run in parallel with the Company\u2019s U.S. controlled launch aimed at building a strong foundation of clinical and commercial advocacy as the Company grows a promising global business. This press release features multimedia. View &hellip; Continue reading &quot;Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-19T13:03:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20210219005136\/en\/860125\/4\/pulse.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch\",\"datePublished\":\"2021-02-19T13:03:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\\\/\"},\"wordCount\":1113,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20210219005136\\\/en\\\/860125\\\/4\\\/pulse.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\\\/\",\"name\":\"Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20210219005136\\\/en\\\/860125\\\/4\\\/pulse.jpg\",\"datePublished\":\"2021-02-19T13:03:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20210219005136\\\/en\\\/860125\\\/4\\\/pulse.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20210219005136\\\/en\\\/860125\\\/4\\\/pulse.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\/","og_locale":"en_US","og_type":"article","og_title":"Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch - Market Newsdesk","og_description":"Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch HAYWARD, Calif.&#8211;(BUSINESS WIRE)&#8211; Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation\u2122 (NPS\u2122) technology, today announced that the first CellFX\u00ae procedures in the European Union were successfully completed. The initial commercial use of the non-thermal, cellular-focused CellFX System to clear common benign lesions, now expands the Company\u2019s controlled launch program starting with the top aesthetic dermatologists and plastic surgeons across Europe. This strategic rollout in Europe will run in parallel with the Company\u2019s U.S. controlled launch aimed at building a strong foundation of clinical and commercial advocacy as the Company grows a promising global business. This press release features multimedia. View &hellip; Continue reading \"Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-19T13:03:24+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20210219005136\/en\/860125\/4\/pulse.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch","datePublished":"2021-02-19T13:03:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\/"},"wordCount":1113,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20210219005136\/en\/860125\/4\/pulse.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\/","name":"Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20210219005136\/en\/860125\/4\/pulse.jpg","datePublished":"2021-02-19T13:03:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20210219005136\/en\/860125\/4\/pulse.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20210219005136\/en\/860125\/4\/pulse.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-announces-first-cellfx-procedures-performed-in-europe-as-part-of-global-controlled-launch\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/439829","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=439829"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/439829\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=439829"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=439829"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=439829"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}